We are live on
!
Find out more
CCMD
Cypress Capital Management (Delaware) Portfolio holdings
AUM
$539M
1-Year Est. Return
11.57%
This Fund
S&P 500
This Quarter
Est. Return
+2.01%
1 Year Est. Return
-11.57%
3 Year Est. Return
+25.57%
5 Year Est. Return
+49.47%
10 Year Est. Return
–
AUM
$287M
AUM Growth
–
Cap. Flow
+$288M
Cap. Flow
% of AUM
100.52%
Top 10 Holdings %
Top 10 Hldgs %
42.37%
Holding
45
New
45
Increased
–
Reduced
–
Closed
–
Avg Time Held
0
quarters
Top 10 Avg Time Held
0
quarters
Top 20 Avg Time Held
0
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$13.5M |
| 2 |
AT&T
T
|
+$13.2M |
| 3 |
State Street SPDR S&P Regional Banking ETF
KRE
|
+$12.7M |
| 4 |
Du Pont De Nemours E I
DD
|
+$12.5M |
| 5 |
Verizon
VZ
|
+$12.5M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.28% |
| 2 | Consumer Discretionary | 13.75% |
| 3 | Miscellaneous | 13.38% |
| 4 | Technology | 12.91% |
| 5 | Energy | 9.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
State Street SPDR S&P Regional Banking ETF
KRE
$3.28B
| $13.4M | 4.68% |
+396,445
| New | +$12.7M |
2013 Q2
0 quarters
|
|
|
2
Pfizer
PFE
$162B
| $13M | 4.53% |
+488,638
| New | +$13.5M |
2013 Q2
0 quarters
|
|
|
3
AT&T
T
$157B
| $12.7M | 4.44% |
+476,770
| New | +$13.2M |
2013 Q2
0 quarters
|
|
|
4
DELISTED
Du Pont De Nemours E I
DD
| $12.4M | 4.32% |
+248,323
| New | +$12.5M |
2013 Q2
0 quarters
|
|
|
5
Verizon
VZ
$181B
| $12.3M | 4.29% |
+244,708
| New | +$12.5M |
2013 Q2
0 quarters
|
|
6
Aptiv
APTV
$9.19B
| $12.1M | 4.2% |
+237,875
| New | +$11.1M |
2013 Q2
0 quarters
|
|
7
Merck
MRK
$350B
| $11.6M | 4.06% |
+262,567
| New | +$11.7M |
2013 Q2
0 quarters
|
|
8
HP
HPQ
$27.6B
| $11.4M | 3.97% |
+1,011,929
| New | +$10.3M |
2013 Q2
0 quarters
|
|
9
GE Aerospace
GE
$319B
| $11.4M | 3.96% |
+102,275
| New | +$11.3M |
2013 Q2
0 quarters
|
|
10
Johnson & Johnson
JNJ
$599B
| $11.2M | 3.92% |
+130,934
| New | +$11.1M |
2013 Q2
0 quarters
|
|
11
PNC Financial Services
PNC
$87.6B
| $10.8M | 3.75% |
+147,590
| New | +$10.2M |
2013 Q2
0 quarters
|
|
12
Lear
LEA
$5.9B
| $10.5M | 3.68% |
+174,430
| New | +$10.1M |
2013 Q2
0 quarters
|
|
13
Helmerich & Payne
HP
$3.91B
| $10.3M | 3.59% |
+165,113
| New | +$10.2M |
2013 Q2
0 quarters
|
|
14
Ford
F
$48.2B
| $10.3M | 3.59% |
+664,960
| New | +$9.53M |
2013 Q2
0 quarters
|
|
15
Vanguard Utilities ETF
VPU
$8.14B
| $9.91M | 3.45% |
+120,533
| New | +$10.3M |
2013 Q2
0 quarters
|
|
16
Intel
INTC
$543B
| $8.94M | 3.12% |
+369,034
| New | +$8.72M |
2013 Q2
0 quarters
|
|
|
GTU
17
DELISTED
CENTRAL GOLD TR (CANADA)
GTU
| $8.8M | 3.07% |
+199,115
| New | +$10.3M |
2013 Q2
0 quarters
|
|
18
Microsoft
MSFT
$4.04T
| $8.66M | 3.02% |
+250,610
| New | +$8.21M |
2013 Q2
0 quarters
|
|
19
Chevron
CVX
$427B
| $8.27M | 2.88% |
+69,869
| New | +$8.44M |
2013 Q2
0 quarters
|
|
20
IBM
IBM
$217B
| $8.05M | 2.81% |
+44,086
| New | +$8.59M |
2013 Q2
0 quarters
|
|
|
STJ
21
DELISTED
St Jude Medical
STJ
| $7.86M | 2.74% |
+172,285
| New | +$7.47M |
2013 Q2
0 quarters
|
|
22
Sprott Physical Gold and Silver Trust
CEF
$7.18B
| $7.46M | 2.6% |
+548,225
| New | +$8.94M |
2013 Q2
0 quarters
|
|
23
State Street Financial Select Sector SPDR ETF
XLF
$51B
| $7.39M | 2.58% |
+433,069
| New | +$7.26M |
2013 Q2
0 quarters
|
|
24
Agilent Technologies
A
$48.4B
| $6.64M | 2.32% |
+217,221
| New | +$6.75M |
2013 Q2
0 quarters
|
|
25
Dana Inc
DAN
$3.06B
| $6.55M | 2.28% |
+339,895
| New | +$6.01M |
2013 Q2
0 quarters
|
|
Similar funds
KPW
SIMS
RTS
KCM
MG
SMG
HPWM
RWA
Cypress Capital Management (Delaware)'s Q2 2013 Portfolio in Review
Q2 2013 is the first quarter with a 13F filing on record for Cypress Capital Management (Delaware), which disclosed 45 positions worth $287M. Its ten largest holdings account for 42% of the portfolio.
Its largest position is Pfizer: 488,638 shares worth $13M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, followed by Consumer Discretionary and Miscellaneous.
- Cypress Capital Management (Delaware)'s largest Q2 2013 buy was Pfizer: 488,638 shares worth $13M.
- Cypress Capital Management (Delaware)'s ten largest holdings make up 42% of its $287M portfolio in Q2 2013.
- Cypress Capital Management (Delaware) disclosed 45 positions in Q2 2013, its first 13F filing on record.
Based on Cypress Capital Management (Delaware)'s 13F filing for Q2 2013, filed 14 Aug 2013.